141 related articles for article (PubMed ID: 37144391)
1. Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.
Caldeira D; Alves da Silva P; Pinto FJ
Stroke; 2023 Jun; 54(6):1656-1659. PubMed ID: 37144391
[TBL] [Abstract][Full Text] [Related]
2. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
3. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
Hart RG; Diener HC; Yang S; Connolly SJ; Wallentin L; Reilly PA; Ezekowitz MD; Yusuf S
Stroke; 2012 Jun; 43(6):1511-7. PubMed ID: 22492518
[TBL] [Abstract][Full Text] [Related]
4. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
Hernandez I; Zhang Y; Brooks MM; Chin PK; Saba S
Stroke; 2017 Jan; 48(1):159-166. PubMed ID: 27909200
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
[TBL] [Abstract][Full Text] [Related]
7. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
10. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
[TBL] [Abstract][Full Text] [Related]
11. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
Reinhardt SW; Desai NR; Tang Y; Jones PG; Ader J; Spertus JA
PLoS One; 2021; 16(8):e0256338. PubMed ID: 34411158
[TBL] [Abstract][Full Text] [Related]
12. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Miao B; Alberts MJ; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation.
Dodson JA; Petrone A; Gagnon DR; Tinetti ME; Krumholz HM; Gaziano JM
JAMA Cardiol; 2016 Apr; 1(1):65-72. PubMed ID: 27437657
[TBL] [Abstract][Full Text] [Related]
15. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
16. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
17. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years.
Tsai CT; Liao JN; Chen SJ; Jiang YR; Chen TJ; Chao TF
Eur J Clin Invest; 2021 Jun; 51(6):e13488. PubMed ID: 33420738
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.
Hori M; Connolly SJ; Zhu J; Liu LS; Lau CP; Pais P; Xavier D; Kim SS; Omar R; Dans AL; Tan RS; Chen JH; Tanomsup S; Watanabe M; Koyanagi M; Ezekowitz MD; Reilly PA; Wallentin L; Yusuf S;
Stroke; 2013 Jul; 44(7):1891-6. PubMed ID: 23743976
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
